Drug Trial Radar · NCT02093923
A Double-Blind, Multiple Ascending Dose Study to Assess Safety, Tolerability and Pharmacokinetics of DX-2930 in Hereditary Angioedema Participants
Last checked: Nov 20, 2026Latest source record: May 27, 2021 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
38
Actual
Start
May 14, 2014
Primary completion
May 18, 2015
Study completion May 18, 2015
Sponsor
- Lead sponsor
- ShireTakeda (TAK)
- Sponsor type
- Industry
- First posted
- Mar 21, 2014
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate the safety, tolerability, and pharmacokinetics (PK) profile of multiple subcutaneous administrations of DX-2930 across a range of doses in HAE participants.
Conditions
- Hereditary Angioedema (HAE)
Interventions
DX-2930Drug
Participants will receive SC injection of DX-2930 (a recombinant, Chinese hamster ovary \[CHO\] cell expressed, fully human immunoglobulin IgG1, kappa light chain, monoclonal antibody) once and followed by the second dose after 2 week into the upper arm.
PlaceboDrug
Participants will receive matching placebo subcutaneously.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants With Serious Adverse Events (SAE) and Treatment-Emergent Adverse Events (TEAE)Time frame: From Day 1 up to final follow-up (Day 123)
Locations
14 sites in 3 countries. Site status is shown where the registry gives one.
UC San Diego Health System - La Jolla
San Diego, California
Allergy & Asthma Clinical Research
Walnut Creek, California
University of South Florida Asthma, Allergy or Immunology Clinical Research Unit
Tampa, Florida
Institute for Asthma & Allergy, PC
Chevy Chase, Maryland
Massachusetts General Hospital Allergy Associates
Boston, Massachusetts
Washington University School of Medicine
St Louis, Missouri
Winthrop-University Hospital, Clinical Trials Center
Mineola, New York
Icahn School of Medicine at Mount Sinai - The Mount Sinai Medical Center
New York, New York
UC Physicians Company
Cincinnati, Ohio
Baker Allergy, Asthma and Dermatology Research Center
Lake Oswego, Oregon
Penn State Hershey Medical Center
Hershey, Pennsylvania
AARA Research Center
Dallas, Texas
Ospedale L. Sacco
Milan, MI, Italy
Jordan University Hospital
Amman, Jordan
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.